GYNECOL ONCOL 2020 10.1016/j.ygyno.2020.02.017
Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer
Choi1, CH; Chung, JY; Kang, JH; Paik, ES; Lee, YY; Park, W; Byeon, SJ; Chung, EJ; Kim, BG; Hewitt, SM; Bae, DS

Front Oncol 2020 10.3389/fonc.2020.00451
Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage I-II High-Risk Endometrial Cancer
Paik1, ES; Baek, SH; Kang, JH; Jeong, SY; Kim, MS; Kim, WY; Lee, YY; Choi, CH; Lee, JW; Kim, BG; Bae, DS; Kim, TJ

CANCER RES TREAT 2020 10.4143/crt.2019.509
Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
Cho1, MA; Jeong, SY; Sohn, I; Kim, MS; Kang, JH; Paik, ES; Lee, YY; Choi, CH

J CLIN MED 2020 10.3390/jcm9041137
Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis
Kim1, J; Chung, JY; Hwang, JR; Lee, YY; Kim, TJ; Lee, JW; Kim, BG; Bae, DS; Choi, CH; Hewitt, SM

CANCER RES TREAT 2020 10.4143/crt.2019.328
Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status
Jeong1, SY; Park, H; Kim, MS; Kang, JH; Paik, ES; Lee, YY; Kim, TJ; Lee, JW; Kim, BG; Bae, DS; Choi, CH

J OBSTET GYNAECOL RE 2020 10.1111/jog.14171
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study
Kim1, SI; Choi, CH; Kim, K; Hong, DH; Park, JY; Kwon, BS; Lee, KH; Hong, DG; Shin, SJ; Park, SI; Kim, YH; Lee, SH; Lee, S; Hong, JH; Lee, JY; Kim, YB; No, JH; Suh, DH

GYNECOL ONCOL 2020 10.1016/j.ygyno.2019.11.004
CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer
Kim1, J; Cho, YJ; Ryu, JY; Hwang, I; Han, HD; Ahn, HJ; Kim, WY; Cho, H; Chung, JY; Hewitt, SM; Kim, JH; Kim, BG; Bae, DS; Choi, CH; Lee, JW

J CLIN MED 2020 10.3390/jcm9010147
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16-or 18-Positive Recurrent Cervical Cancer
Choi1, CH; Choi, HJ; Lee, JW; Kang, ES; Cho, D; Park, BK; Kim, YM; Kim, DY; Seo, H; Park, M; Kim, W; Choi, KY; Oh, T; Kang, CY; Kim, BG

CANCER RES TREAT 2020 10.4143/crt.2019.124
Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028)
Paik1, ES; Lim, MC; Kim, MH; Kim, YH; Song, ES; Seong, SJ; Suh, DH; Lee, JM; Lee, C; Choi, CH

Cancer Res Treat. 2019 Aug 5. doi: 10.4143/crt.2019.124. [Epub ahead of print]
Prognostic Model for Survival and Recurrence in Patients with Early Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028)
Paik ES1, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, Suh DH, Lee JM, Lee C, Choi CH.

J OVARIAN RES 2019 10.1186/s13048-019-0602-5
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
Jeong1, SY; Choi, CH; Kim, TJ; Lee, JW; Kim, BG; Bae, DS; Lee, YY

J GYNECOL ONCOL 2019 10.3802/jgo.2019.30.e112
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
Lee1, JY; Kim, JW; Lim, MC; Kim, S; Kim, HS; Choi, CH; Yi, JY; Park, SY; Kim, BG; Nam, EJ; Kim, SW; Eoh, KJ; Lee, YJ; Roh, J; Kim, HM; Rae, DS; Lee, JW; Kim, TJ; Lee, YY; Choi, EH; Song, S; Kim, HS; Lee, M; Kim, SI; Lee, EJ; Kwon, SI; Shin, W; Seo, SS; Kang, S; Kim, MS; Kim, JS; Joung, J; Chung, J

J CLIN MED 2019 10.3390/jcm8111920
Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
Paik1, ES; Lee, YJ; Lee, JY; Shin, W; Park, SY; Kim, SI; Kim, JW; Choi, CH; Kim, BG

EUR RADIOL 2019 10.1007/s00330-019-06204-w
Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy
Gu1, KW; Kim, CK; Choi, CH; Yoon, YC; Park, W

SCI REP-UK 2019 10.1038/s41598-019-51959-3
Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer
Lee1, YY; Cho, YJ; Shin, SW; Choi, C; Ryu, JY; Jeon, HK; Choi, JJ; Hwang, JR; Choi, CH; Kim, TJ; Kim, BG; Bae, DS; Park, W; Lee, JW

GYNECOL ONCOL 2019 10.1016/j.ygyno.2019.06.023
Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028)
Paik1, ES; Lim, MC; Kim, MH; Kim, YH; Song, ES; Seong, SJ; Suh, DH; Lee, JM; Lee, C; Choi, CH

EUR J GYNAECOL ONCOL 2019 10.12892/ejgo4827.2019
Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report
Noh1, JJ; Jung, H; Choi, CH

JPN J CLIN ONCOL 2019 10.1093/jjco/hyz085
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Lee1, JY; Yi, JY; Kim, HS; Lim, J; Kim, S; Nam, BH; Kim, HS; Kim, JW; Choi, CH; Kim, BG

J GYNECOL ONCOL 2019 10.3802/jgo.2019.30.e65
Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods
Paik1, ES; Lee, JW; Park, JY; Kim, JH; Kim, M; Kim, TJ; Choi, CH; Kim, BG; Bae, DS; Seo, SW

J GYNECOL ONCOL 2019 10.3802/jgo.2019.30.e11
Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim1, J; Chang, Y; Kim, TJ; Lee, JW; Kim, BG; Bae, DS; Choi, CH

CANCER RES TREAT 2019 10.4143/crt.2017.361
Development and Validation of Ovarian Symptom Index-18 and Neurotoxcity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lee1, M; Lee, Y; Kim, K; Park, EY; Lim, MC; Kim, JS; Kim, HS; Kim, YB; Kim, YM; Joo, J; Park, SY; Choi, CH; Kim, JH
외 다수